



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Anti-PAI-1 [MEDI-579] Standard Size Ab03644-30.11

This is an scFv fragment with a His tag.

This is a reformatted human scFv antibody, based on the original human scFv format, created for improved compatibility with existing reagents, assays and techniques.

Isotype and Format: scFv fragment (His), ScFv

Clone Number: MEDI-579

Alternative Name(s) of Target: SERPINE1; PAI1; PAI; PLANH1; Plasminogen activator inhibitor 1; Endothelial plasminogen activator inhibitor; Serpin E1; Humanized Ab167; MEDI579; Antibody 08

UniProt Accession Number of Target Protein: P05121

Published Application(s): inhibit, neutralize, ELISA

Published Species Reactivity: Rat, Human, Mouse

Immunogen: The original antibody was isolated from a human scFv library by panning on recombinant human and rat PAI-1 followed by screening in a PAI-1/tPA competition binding assay.

Specificity: This antibody binds the reactive center loop (RCL) of human PAI-1 and at the same exosite used by both tissue and urokinase plasminogen activators (tPA and uPA). This antibody binds the active form of human PAI-1. Plasminogen activator inhibitor-1 (PAI-1), is a serine protease inhibitor, a unique member of the serpin superfamily which plays an important role in fibrinolysis and is an established risk factor for cardiovascular diseases. It a primary inhibitor of tissue-type plasminogen activator (PLAT) and urokinase-type plasminogen activator (PLAU). As PLAT inhibitor, it is required for fibrinolysis down-regulation and is responsible for the controlled degradation of blood clots. As PLAU inhibitor, it is involved in the regulation of cell adhesion and spreading .

Application Notes: This antibody specifically inhibits serine protease interactions with PAI-1 while conserving vitronectin binding. The binding of this antibody to native and latent form of human PAI-1 was determined using ELISA. This antibody was able to neutralize recombinant human, rat and mouse PAI-1 activity in species-relevant tPA-coupled chromogenic assays. The Fab version of this antibody binds human and rat PAI-1 with a binding affinity (Kd) of 5.34 pM and 84 pM respectively. Competition binding experiments also demonstrates that MEDI-579 does not interact with other circulating serpins (PMID: 30733557). This antibody is effective in slowing the progression of diabetic nephropathy in db/db mice and that the effect is additive to ACEI (PMID: 27511457).

Antibody First Published in: Vousden et al. Discovery and characterization of an antibody that selectively modulates the inhibitory activity of plasminogen activator inhibitor-1. Sci Rep. 2019 Feb

7;9(1):1605. [PMID:30733557](#)

Note on publication: Describes the generation and characterization of this antibody.

Product Form

Size: 100 µg Purified antibody.

Purification: Purified by Immobilized Metal Affinity Chromatography

Supplied In: PBS with 0.02% Proclin 300.

Storage Recommendation: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Concentration: 1 mg/ml.

Important note - This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.